Integrating Phase 2 Into Phase 3 Based on an Intermediate Endpoint While Accounting for a Cure Proportion—With an Application to the Design of a Clinical Trial in Acute Myeloid Leukemia
Pharmaceutical Statistics - United Kingdom
doi 10.1002/pst.1969
Full Text
Open PDFAbstract
Available in full text
Date
August 28, 2019
Authors
Publisher
Wiley